23rd June 2020
- 0 comments
Epidarex Capital, a transatlantic life science venture firm, announces that it has closed Epidarex Capital III UK LP at £102.1 million. The Fund will build new life science companies based on world-class research and innovation from emerging hubs across the UK, including spinouts from highly regarded universities. Typical initial investments will range from £2 million to £5 million.
...In order to read the full story we need you to be registered with us, please click the links below to login or register.